iRobot Corporation (IRBT)
NASDAQ: IRBT · Real-Time Price · USD
4.220
-0.270 (-6.01%)
At close: Aug 6, 2025, 4:00 PM
4.260
+0.040 (0.95%)
After-hours: Aug 6, 2025, 7:59 PM EDT
Achilles Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 29, 2025 | Dec '24 Dec 28, 2024 | Dec '23 Dec 30, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Jan '21 Jan 2, 2021 | 2016 - 2020 |
Revenue | 633.4 | 681.85 | 890.58 | 1,183 | 1,565 | 1,430 | Upgrade |
Revenue Growth (YoY) | -28.05% | -23.44% | -24.74% | -24.38% | 9.41% | 17.82% | Upgrade |
Cost of Revenue | 499.99 | 534.3 | 693.31 | 825.47 | 1,013 | 758.24 | Upgrade |
Gross Profit | 133.42 | 147.55 | 197.28 | 357.92 | 551.52 | 672.15 | Upgrade |
Selling, General & Admin | 204.32 | 210.46 | 285.6 | 388.36 | 389.04 | 360.8 | Upgrade |
Research & Development | 74.09 | 93.28 | 143.53 | 165.22 | 161.33 | 156.67 | Upgrade |
Operating Expenses | 279.92 | 305.29 | 430.76 | 557.85 | 552.62 | 520.38 | Upgrade |
Operating Income | -146.51 | -157.74 | -233.49 | -199.93 | -1.1 | 151.77 | Upgrade |
Interest Expense | -34.33 | -22.07 | -24.69 | -1.88 | -0.02 | - | Upgrade |
Interest & Investment Income | 6.75 | 7.93 | 5.62 | 1.41 | 0.53 | - | Upgrade |
Currency Exchange Gain (Loss) | 0.64 | 2.23 | -0.12 | 2.95 | -9.78 | -0.19 | Upgrade |
Other Non Operating Income (Expenses) | -28.57 | -5.34 | 0.04 | -4.07 | 8.59 | -2.04 | Upgrade |
EBT Excluding Unusual Items | -202.03 | -175.01 | -252.65 | -201.51 | -1.78 | 149.54 | Upgrade |
Merger & Restructuring Charges | -27.59 | 41.29 | -25.69 | -29.36 | - | - | Upgrade |
Gain (Loss) on Sale of Investments | 0.01 | -0.37 | -3.91 | -19.72 | 30.06 | 43.82 | Upgrade |
Asset Writedown | - | - | -4.9 | -11.1 | - | - | Upgrade |
Legal Settlements | 13.5 | 13.5 | - | - | - | -5.44 | Upgrade |
Other Unusual Items | -24.56 | -24.56 | -5.9 | - | - | - | Upgrade |
Pretax Income | -240.67 | -145.14 | -293.06 | -261.68 | 28.28 | 187.92 | Upgrade |
Income Tax Expense | 0.73 | 0.38 | 11.66 | 24.61 | -2.11 | 40.85 | Upgrade |
Net Income | -241.4 | -145.52 | -304.71 | -286.3 | 30.39 | 147.07 | Upgrade |
Net Income to Common | -241.4 | -145.52 | -304.71 | -286.3 | 30.39 | 147.07 | Upgrade |
Net Income Growth | - | - | - | - | -79.34% | 72.41% | Upgrade |
Shares Outstanding (Basic) | 30 | 30 | 28 | 27 | 28 | 28 | Upgrade |
Shares Outstanding (Diluted) | 30 | 30 | 28 | 27 | 28 | 29 | Upgrade |
Shares Change (YoY) | 8.57% | 6.95% | 1.70% | -3.37% | -1.59% | -0.41% | Upgrade |
EPS (Basic) | -7.98 | -4.92 | -11.01 | -10.52 | 1.10 | 5.23 | Upgrade |
EPS (Diluted) | -7.98 | -4.92 | -11.01 | -10.52 | 1.08 | 5.14 | Upgrade |
EPS Growth | - | - | - | - | -78.99% | 73.06% | Upgrade |
Free Cash Flow | -61.12 | -33.34 | -117.66 | -102.35 | -61.9 | 200.45 | Upgrade |
Free Cash Flow Per Share | -2.02 | -1.13 | -4.25 | -3.76 | -2.20 | 7.00 | Upgrade |
Gross Margin | 21.06% | 21.64% | 22.15% | 30.25% | 35.24% | 46.99% | Upgrade |
Operating Margin | -23.13% | -23.14% | -26.22% | -16.89% | -0.07% | 10.61% | Upgrade |
Profit Margin | -38.11% | -21.34% | -34.22% | -24.19% | 1.94% | 10.28% | Upgrade |
Free Cash Flow Margin | -9.65% | -4.89% | -13.21% | -8.65% | -3.96% | 14.01% | Upgrade |
EBITDA | -128.83 | -136.88 | -207 | -165.36 | 29.91 | 184.43 | Upgrade |
EBITDA Margin | -20.34% | -20.07% | -23.24% | -13.97% | 1.91% | 12.89% | Upgrade |
D&A For EBITDA | 17.68 | 20.87 | 26.49 | 34.57 | 31.01 | 32.66 | Upgrade |
EBIT | -146.51 | -157.74 | -233.49 | -199.93 | -1.1 | 151.77 | Upgrade |
EBIT Margin | -23.13% | -23.13% | -26.22% | -16.89% | -0.07% | 10.61% | Upgrade |
Effective Tax Rate | - | - | - | - | - | 21.74% | Upgrade |
Advertising Expenses | - | 50.7 | 87.7 | 146.6 | 147.2 | 145.2 | Upgrade |
Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.